AGT Stock Chart & Stats
€115.70
€1.00(0.87%)
At close: 4:00 PM EDT
€115.70
€1.00(0.87%)
Day’s Range― - ―
52-Week Range€93.75 - €137.50
Previous CloseN/A
Volume0.00
Average Volume (3M)55.00
Market Cap
€7.68B
Enterprise Value€9.39K
Total Cash (Recent Filing)€229.48M
Total Debt (Recent Filing)€1.41B
Price to Earnings (P/E)23.3
Beta0.47
Next Earnings
Oct 29, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.91
Shares Outstanding63,820,316
10 Day Avg. Volume29
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG Ratio3.61
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.31Price Target Upside12.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)4.78
Revenue Forecast (FY)€3.47B
Bulls Say, Bears Say
Bulls Say
Recurring Design‑in, Unit-volume Business ModelAptar’s core business is repeatable, unit-volume manufacturing with long qualification cycles that embed its components into customer products. This creates durable revenue visibility, high customer switching costs, and recurring order flow across Beauty, Closures and Pharma, supporting stable medium-term cash generation.
Pharma Franchise And Pipeline ProgressAptar’s pharma segment benefits from regulatory barriers and validated device platforms. Growth in injectables and consumer healthcare, plus Phase‑2 programs and label/approval wins, underpin multi-year revenue potential and premium product pricing versus commodity packaging, strengthening long-term organic growth prospects.
Solid Operating Cash Flow And Free Cash FlowConsistent operating cash conversion and rising FCF give Aptar capacity to fund capex, R&D, dividends and share repurchases without relying solely on external financing. This cash generation supports investment in capacity and innovation that sustain competitive advantage over a multi‑quarter horizon.
Bears Say
TTM Equity Anomaly And Elevated Leverage RiskThe anomalously low TTM equity and resultant sky-high debt-to-equity ratio materially increase financial risk. If sustained, this constrains borrowing flexibility, raises refinancing and covenant risk, and limits capacity to fund strategic investments or absorb shocks without more costly capital actions over the coming quarters.
Sharp TTM Gross‑margin Step‑downA large decline in reported gross margins signals meaningful cost, mix or pricing pressure that can erode sustainable profitability. If structural (not just timing or one-offs), lower gross margins reduce operating leverage, constrain reinvestment and compress long‑run EBITDA margins even as volumes recover.
Rising Input Costs And Margin VolatilityEscalating raw material, transport and energy costs create persistent margin pressure when indexation or pass-through lags. Combined with recurring operational disruptions, this produces volatile segment margins and complicates forecasting and pricing negotiations, reducing margin reliability across multiple quarters.
AptarGroup News
AGT FAQ
What was AptarGroup’s price range in the past 12 months?
AptarGroup lowest stock price was €93.75 and its highest was €137.50 in the past 12 months.
What is AptarGroup’s market cap?
AptarGroup’s market cap is €7.68B.
When is AptarGroup’s upcoming earnings report date?
AptarGroup’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were AptarGroup’s earnings last quarter?
AptarGroup released its earnings results on Jul 30, 2026. The company reported €1.234 earnings per share for the quarter, beating the consensus estimate of €1.176 by €0.057.
Is AptarGroup overvalued?
According to Wall Street analysts AptarGroup’s price is currently Undervalued.
Does AptarGroup pay dividends?
AptarGroup does not currently pay dividends.
What is AptarGroup’s EPS estimate?
AptarGroup’s EPS estimate is 1.27.
How many shares outstanding does AptarGroup have?
AptarGroup has 63,820,316 shares outstanding.
What happened to AptarGroup’s price movement after its last earnings report?
AptarGroup reported an EPS of €1.234 in its last earnings report, beating expectations of €1.176. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AptarGroup?
Currently, no hedge funds are holding shares in DE:AGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AptarGroup Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€130.31 (12.62% Upside)
€130.31 (12.62% Upside)
Blogger Sentiment
Bullish
DE:AGT Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.25%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
12.61%
Trailing 12-Months
Company Description
AptarGroup
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
AGT Company Deck
AGT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: solid cash generation, product wins, meaningful pharma pipeline progress and targeted investments underpin medium-to-long-term growth. However, near-term headwinds—most notably a ~$65 million emergency medicine destock, margin compression across segments (Beauty and Closures), operational disruptions, and rising input costs—create tangible short-term pressure on profitability. Management expects sequential improvement and has provided a Q2 EPS range and full-year investment outlook, but near-term metrics reflect a mix of positive commercial momentum and notable operational and cost challenges.View all DE:AGT earnings summariesAGT Stock 12 Month Forecast
Average Price Target
€130.31
▲(12.62% Upside)
Technical Analysis
Baxter International
―
Cooper Co
―
Repligen
―
West Pharmaceutical Services
―
Stevanato Group
―